Major EuroPCR 2025 LBT - 4D-ACS: one-month DAPT followed by dose reduction of prasugrel after drug-coated stent insertion in acute coronary syndrome
In this #europcr 2025 interview, Davide Capodanno and Woong Chol Kang explore the latest insights from the 4D-ACS trial and what it could mean for antithrombotic therapy in patients with acute coronary syndrome.
They discuss who was included in the trial and walk through the two de-escalation strategies that were tested: reducing the number of the drugs, from dual antiplatelet therapy to single antiplatelet therapy, and lowering the prasugrel dose from 10 mg to 5 mg.
Finally, they highlight the key findings that could help refine clinical practice.
Listen now to get up to speed in just a few…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.